As of November, NBS was 10 patients shy of reaching full enrollment for its Phase 2 trial. Let me say it again, 10 PATIENTS SHY! The announcement of complete enrollment could come any day, or at any second!
Once that happens, NBS will soar at least 10% because it means we are 6-9 months from final data. AMR-001 already has good data, and Baxter's data has been remarkable with its CD34+ product.
There will be a lot of anticipation and NBS will get a pre-data run higher. The stock could easily be $11 by the time data is announced, and if positive, NBS will be a $25 stock.
If for some reason data is bad, unlikely, NBS will be a $4 stock. Therefore, assess the upside/downside and you'll see that there's not much to lose, but a lot to gain.
All results to date have been positive. The number of participating sites with zero news on negative outcomes thus far means the beneficial results of trial will continue. I think $25 is a bit of a stretch but $20 is very realistic.
I think it's hard to predict whether the stock will be a $20 or $25 or even a $30+ stock, but what I do know is that the stock will continue to climb as the company grows. As far as high-risk investments go, NBS is where I'd want to be. I feel like this is the lowest high-risk investment out there. I feel safe that my money will continue to grow with the company.